CONVATEC Grp PL/ADR (OTCMKTS:CNVVY) was downgraded by equities researchers at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a note issued to investors on Tuesday, October 16th, The Fly reports.
A number of other equities research analysts also recently commented on the stock. Jefferies Financial Group began coverage on shares of CONVATEC Grp PL/ADR in a report on Wednesday, October 3rd. They set a “buy” rating for the company. Goldman Sachs Group downgraded shares of CONVATEC Grp PL/ADR from a “buy” rating to a “neutral” rating in a report on Tuesday, October 16th.
CNVVY traded down $0.28 during midday trading on Tuesday, reaching $7.96. 177 shares of the company’s stock were exchanged, compared to its average volume of 51,795. CONVATEC Grp PL/ADR has a 1-year low of $7.42 and a 1-year high of $12.61.
ConvaTec Group Plc is a holding company, which engages in medical business. Its activities include development, manufacture and sales of medical products and technologies related to therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care and management, continence and critical care, and infusion devices used in the treatment of diabetes and other conditions.
Featured Story: Terms to Better Understand Call Options
Receive News & Ratings for CONVATEC Grp PL/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONVATEC Grp PL/ADR and related companies with MarketBeat.com's FREE daily email newsletter.